CPG
ABCL icon

Cornerstone Planning Group’s AbCellera Biologics ABCL Stock Holding History

Cornerstone Planning Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Hold
2,000
– – ﹤0.01% 852
2026
Q1 		$9.32K Buy
2,000
+250
+14% +$900 ﹤0.01% 915
2025
Q4 		$6.83K Buy
1,750
+1,716
+5,047% +$7.66K ﹤0.01% 892
2025
Q3 		$741 Buy
+34
New +$150 ﹤0.01% 1385

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Cornerstone Planning Group's ABCL Position: Q2 2026 in Review

Cornerstone Planning Group held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 2,000 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Cornerstone Planning Group first reported a position in ABCL in Q3 2025 and has held it in 4 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Cornerstone Planning Group held 2,000 shares of AbCellera Biologics worth $11.5K as of Q2 2026.
  • Cornerstone Planning Group left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #852 holding.
  • Cornerstone Planning Group first reported a position in AbCellera Biologics in Q3 2025 and has held it in 4 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.